Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Senti Biosciences (SNTI) EBITDA (2021 - 2025)

Senti Biosciences has reported EBITDA over the past 5 years, most recently at -$14.5 million for Q4 2025.

  • Quarterly results put EBITDA at -$14.5 million for Q4 2025, down 2271.64% from a year ago — trailing twelve months through Dec 2025 was -$61.4 million (down 16.38% YoY), and the annual figure for FY2025 was -$61.4 million, down 16.38%.
  • EBITDA for Q4 2025 was -$14.5 million at Senti Biosciences, up from -$18.1 million in the prior quarter.
  • Over the last five years, EBITDA for SNTI hit a ceiling of -$1178.0 in Q1 2021 and a floor of -$28.9 million in Q3 2024.
  • Median EBITDA over the past 5 years was -$14.3 million (2025), compared with a mean of -$13.9 million.
  • Biggest five-year swings in EBITDA: plummeted 1002276.91% in 2022 and later surged 96.74% in 2024.
  • Senti Biosciences' EBITDA stood at -$10.9 million in 2021, then crashed by 66.99% to -$18.2 million in 2022, then dropped by 2.78% to -$18.7 million in 2023, then surged by 96.74% to -$610000.0 in 2024, then crashed by 2271.64% to -$14.5 million in 2025.
  • The last three reported values for EBITDA were -$14.5 million (Q4 2025), -$18.1 million (Q3 2025), and -$14.7 million (Q2 2025) per Business Quant data.